Breast cancer prevention study: are healthy women put at risk by federally funded research? : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, second session, October 22, 1992
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
adjuvant BCPT bone Bowel Project Breast Cancer Action breast cancer prevention breast tumors Cancer Prevention Trial cardiovascular centers Chairman cholesterol clinical trials concern consent document contralateral breast developing breast cancer Director disease dose effects of tamoxifen eligible endometrial cancer estrogen Evaluation evidence exam Food and Drug GREENWALD Gregory Burke healthy women HEALY high risk hormone human increased risk informed consent informed consent form institutional review board known risks liver cancer minority women model informed consent National Cancer Institute National Surgical Adjuvant NSABP Oncology osteoporosis participate patients PAYNE percent physician placebo population postmenopausal postmenopausal women premenopausal women prevent breast cancer protocol public health questions rats receiving tamoxifen recruitment reduce reported risk factors risk of breast risk of developing risks and benefits side effects subcommittee subjects taking tamoxifen tamoxifen study tests toxicity treatment uterine cancer woman Women's Health yean